Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks

Lillibeth Chaverra-Muñoz,Theresa Briem,Stephan Hüttel
DOI: https://doi.org/10.1186/s12934-022-01827-z
IF: 6.352
2022-05-29
Microbial Cell Factories
Abstract:The fungal sesquiterpenes Illudin M and S are important base molecules for the development of new anticancer agents due to their strong activity against some resistant tumor cell lines. Due to nonspecific toxicity of the natural compounds, improvement of the pharmacophore is required. A semisynthetic derivative of illudin S (Irofulven) entered phase II clinical trials for the treatment of castration-resistant metastatic prostate cancer. Several semisynthetic illudin M derivatives showed increased in vitro selectivity and improved therapeutic index against certain tumor cell lines, encouraging further investigation. This requires a sustainable supply of the natural compound, which is produced by Basidiomycota of the genus Omphalotus . We aimed to develop a robust biotechnological process to deliver illudin M in quantities sufficient to support medicinal chemistry studies and future preclinical and clinical development. In this study, we report the initial steps towards this goal.
biotechnology & applied microbiology
What problem does this paper attempt to address?